Insider Selling: Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Sells 9,477 Shares of Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Padmanabh P. Bhatt sold 9,477 shares of the company’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total value of $376,236.90. Following the sale, the vice president now owns 10,149 shares in the company, valued at approximately $402,915.30. This represents a 48.29 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN stock traded down $0.52 during midday trading on Wednesday, hitting $39.48. 310,305 shares of the company were exchanged, compared to its average volume of 362,931. The firm has a market capitalization of $2.18 billion, a P/E ratio of 36.90 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a 52 week low of $25.53 and a 52 week high of $40.28. The firm’s 50 day moving average price is $37.24 and its two-hundred day moving average price is $34.66.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.25. The firm had revenue of $175.70 million during the quarter, compared to the consensus estimate of $157.35 million. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The company’s revenue was up 14.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.29) EPS. Analysts expect that Supernus Pharmaceuticals, Inc. will post 2.38 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its stake in shares of Supernus Pharmaceuticals by 97.1% in the 3rd quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock valued at $25,000 after purchasing an additional 398 shares in the last quarter. Smartleaf Asset Management LLC boosted its holdings in shares of Supernus Pharmaceuticals by 219.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 870 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Supernus Pharmaceuticals by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock worth $61,000 after acquiring an additional 352 shares during the last quarter. Newbridge Financial Services Group Inc. acquired a new position in Supernus Pharmaceuticals in the 4th quarter worth about $72,000. Finally, Venturi Wealth Management LLC bought a new position in Supernus Pharmaceuticals in the fourth quarter valued at about $92,000.

Wall Street Analyst Weigh In

SUPN has been the topic of several analyst reports. Cantor Fitzgerald began coverage on shares of Supernus Pharmaceuticals in a research report on Monday, January 6th. They set an “overweight” rating and a $57.00 price target on the stock. Piper Sandler reiterated a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Finally, Cowen restated a “buy” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.